BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

First Quarter 2026 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management's call and presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. I would now like to turn over the call to Chuck Pallada, Investor Relations. Chuck, please go ahead. Thank you, Operator, and welcome, everyone, and thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. I'd like to remind everyone that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20F and our quarterly reports on Form 6K that are filed with the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BylineRx. Thank you, Chuck, and good morning, everyone. And thank you for joining us on today's call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Molly Zeffi, our chief financial officer, to briefly recap our financials. Afterwards, we will take your questions. Ella Surani, our chief development officer, is also available for Q&A. I would like to begin this morning with an update on GLIX-1, a highly innovative molecule for the treatment of glioblastoma, or GBM, and other cancers that we obtained ...